Switch theme
Sign up to access all valuation multiples
Ambu AS is a Denmark based company providing single-use flexible endoscopes and is dedicated to optimizing hospital workflows and improving patient care. The company has created medtech solutions like resuscitators, anaesthesia masks, and electrodes and operates R&D, manufacturing and sales in Europe, North America and Rest of the world.
1937
5.2K+
LTM Revenue $839M
LTM EBITDA $164M
$4.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ambu has a last 12-month revenue of $839M and a last 12-month EBITDA of $164M.
In the most recent fiscal year, Ambu achieved revenue of $776M and an EBITDA of $98.2M.
Ambu expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ambu valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $687M | $776M | XXX | XXX | XXX |
| Gross Profit | $368M | $391M | XXX | XXX | XXX |
| Gross Margin | 53% | 50% | XXX | XXX | XXX |
| EBITDA | $89.1M | $98.2M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 13% | XXX | XXX | XXX |
| Net Profit | $13.4M | $24.2M | XXX | XXX | XXX |
| Net Margin | 2% | 3% | XXX | XXX | XXX |
| Net Debt | $153M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ambu's stock price is DKK 118 (or $17).
Ambu has current market cap of DKK 31.6B (or $4.5B), and EV of DKK 31.5B (or $4.5B).
See Ambu trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.5B | $4.5B | XXX | XXX | XXX | XXX | $0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ambu has market cap of $4.5B and EV of $4.5B.
Ambu's trades at 5.4x LTM EV/Revenue multiple, and 27.7x LTM EBITDA.
Analysts estimate Ambu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ambu and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.5B | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | 38.1x | XXX | XXX | XXX |
| P/E | 88.9x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | 59.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAmbu's NTM/LTM revenue growth is 13%
Ambu's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Ambu's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ambu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ambu and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 28% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ambu acquired XXX companies to date.
Last acquisition by Ambu was XXXXXXXX, XXXXX XXXXX XXXXXX . Ambu acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ambu founded? | Ambu was founded in 1937. |
| Where is Ambu headquartered? | Ambu is headquartered in Denmark. |
| How many employees does Ambu have? | As of today, Ambu has 5.2K+ employees. |
| Who is the CEO of Ambu? | Ambu's CEO is Ms. Britt Meelby Jensen. |
| Is Ambu publicy listed? | Yes, Ambu is a public company listed on CSE. |
| What is the stock symbol of Ambu? | Ambu trades under AMBU B ticker. |
| When did Ambu go public? | Ambu went public in 1993. |
| Who are competitors of Ambu? | Similar companies to Ambu include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Ambu? | Ambu's current market cap is $4.5B |
| What is the current revenue of Ambu? | Ambu's last 12-month revenue is $839M. |
| What is the current EBITDA of Ambu? | Ambu's last 12-month EBITDA is $164M. |
| What is the current EV/Revenue multiple of Ambu? | Current revenue multiple of Ambu is 5.4x. |
| What is the current EV/EBITDA multiple of Ambu? | Current EBITDA multiple of Ambu is 27.7x. |
| What is the current revenue growth of Ambu? | Ambu revenue growth between 2023 and 2024 was 13%. |
| Is Ambu profitable? | Yes, Ambu is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
